E' scientifico: più contraccezione = più aborti
Trends in the use of contraceptive methods and voluntary interruption of pregnancy in the Spanish population during 1997–2007?Received 18 May 2009; received in revised form 11 May 2010; accepted 12 May 2010. published online 18 June 2010.
BackgroundThis study was designed to acquire information about the use of contraceptive methods in order to reduce the number of elective abortions.
Study DesignSince 1997, representative samples of Spanish women of childbearing potential (15–49 years) have been surveyed by the Daphne Team every 2 years to gather data of contraceptive methods used.
ResultsDuring the study period, 1997 to 2007, the overall use of contraceptive methods increased from 49.1% to 79.9%. The most commonly used method was the condom (an increase from 21% to 38.8%), followed by the pill (an increase from 14.2% to 20.3%). Female sterilization and IUDs decreased slightly and were used by less than 5% of women in 2007. The elective abortion rate increased from 5.52 to 11.49 per 1000 women.
ConclusionsThe factors responsible for the increased rate of elective abortion need further investigation.
a Department of Obstetrics and Gynecology, Hospital Universitario Virgen Macarena, E-41009 Sevilla, Spain b Department of Obstetrics and Gynecology, Hospital Santiago Apóstol, E-01004 Vitoria-Gasteiz, Spain c Medical Department, Bayer Schering Pharma, E-08037 Barcelona, Spain d Department of Obstetrics and Gynecology, Hospital General de Requena, E-46340 Requena, Valencia, Spain e Department of Obstetrics and Gynecology, Hospital Severo Ochoa, E-28911 Leganés, Madrid, Spain f Centro Joven Madrid Salud y Programas de Planificación Familiar y Salud Materno-Infantil, Ayuntamiento de Madrid, E-28015 Madrid, Spain g Department of Obstetrics and Gynecology, Hospital Cristal Piñor, E-32005 Ourense, Spain h PASSIR (Programa d'Atenció a la Salut Sexual i Reproductiva), Barcelonès Nord i Maresme, Institut Català de la Salut, E-08913 Barcelona, SpainCorresponding author. Tel.: +34 955 008899, fax: +34 954 551790.
? Funding: This study was conducted with an educational grant from Bayer Schering Pharma.PII: S0010-7824(10)00327-6 doi:10.1016/j.contraception.2010.05.010 © 2011 Elsevier Inc. All rights reserved.